黄斑変性症（AMD）とその他の網膜疾患治療薬の市場レポート：2022-2032

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

レポート詳細黄斑変性症（AMD）とその他の網膜疾患治療薬の市場レポート 2022-2032 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2022年11月25日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	276	273	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

レポート詳細

黄斑変性症（AMD）とその他の網膜疾患治療薬の市場レポート 2022-2032:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

網膜疾患の発症率上昇
発展途上国では、網膜失明症のパターンが時代とともに変化しています。10年前までは、網膜疾患による視覚障害の主な原因は遺伝性網膜障害でした。網膜失明症には、糖尿病性網膜症、加齢黄斑変性症（AMD）、未熟児網膜症（ROP）など、重要かつ増加傾向にある原因がいくつかあります。2025年までに、インドには5,700万人の糖尿病患者と1億3,700万人の65歳以上の高齢者が住むと予測されています。2030年には、先進国で4,200万人以上、発展途上国で8,200万人以上の糖尿病患者が発生すると推計されています。発展途上国では、パキスタンとバングラデシュを除き、AMDの有病率は0.6％から1.1％です。WHOの基準によると、世界には150万人の盲目の子供がおり、そのうち100万人がアジアに、30万人がアフリカに、10万人がラテンアメリカに、それ以外の地域に住んでいると言われています。ROPは、新生児集中治療室（NICU）や三次医療機関に紹介された後、21～40％の確率で発生します。この予防と治療が可能な網膜の失明原因と戦うために、健康教育やプロモーション、簡単に利用できる眼科医療サービス、インフラの強化、手頃な価格の技術などの手段を採用することが有効であると思われます。

マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- 黄斑変性症（AMD）とその他の網膜疾患治療薬市場はどのように進化しているのか？
- 黄斑変性症（AMD）とその他の網膜疾患治療薬市場の推進要因と抑制要因は何か？
- 黄斑変性症（AMD）とその他の網膜疾患治療薬の各サブマーケット区分は予測期間中にどのように成長し、2032年にこれらのサブマーケットが占める売上はどの程度になるのでしょうか？
- 2022年から2032年にかけて、黄斑変性症（AMD）とその他の網膜疾患治療薬の各サブマーケットの市場シェアはどのように推移するのでしょうか？
- 2022年から2032年にかけて、市場全体の主なドライバーは何になるのか？
- 黄斑変性症（AMD）とその他の網膜疾患治療薬の主要市場はマクロ経済のダイナミクスに概ね追随するのか、それとも個々の国内市場が他を凌駕するのか？
- 2032年までに各国市場のシェアはどのように変化し、どの地域が2032年に市場をリードするのでしょうか？
- 主要プレイヤーは誰か、また予測期間中の見通しは？
- これらの主要企業の黄斑変性症（AMD）とその他の網膜疾患治療薬のプロジェクトは？
- 2022年から2032年の間に、業界はどのように進化していくのでしょうか？現在および今後10年間に行われる黄斑変性症（AMD）とその他の網膜疾患治療薬のプロジェクトはどのような意味を持つのか？
- 黄斑変性症（AMD）とその他の網膜疾患治療薬の市場をさらに拡大するために、製品の商業化の必要性は高いか？
- 黄斑変性症（AMD）とその他の網膜疾患治療薬市場はどこに向かい、どのようにすれば市場の最前線に立つことができるか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

このことが黄斑変性症（AMD）とその他の網膜疾患治療薬市場に現在、そして今後10年間、どのような影響を及ぼすかを知る必要があります。

-276ページにわたる本レポートでは、123の表と150のグラフを独占的に提供します。
- このレポートでは、業界における主要な収益性の高い分野をハイライトしているため、今すぐターゲットを絞ることができます。
- 世界、地域、国別の売上高と成長率を詳細に分析しています。
- 競合他社が成功した主要なトレンド、変化、収益予測をハイライトしています。

本レポートは、黄斑変性症（AMD）とその他の網膜疾患治療薬市場が今後10年間にどのように発展するか、またCOVID-19の景気後退とバウンスの変動に合わせて、今日あなたにお伝えします。この市場は、過去10年間のどの時点よりも、今がより重要なのです。

2032年までの予測やその他の分析により、商業的な展望が見えてくる
- 2032年までの収益予測に加え、直近の実績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望や展開など、独自の分析もご覧いただけます。
- 定性的分析（市場力学、ドライバー、機会、阻害要因、課題など）、コスト構造、黄斑変性症（AMD）とその他の網膜疾患治療薬の価格上昇の影響、最近の開発状況をご覧いただけます。

本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。

報告書の対象セグメント

適応症
- AMD
- 糖尿病黄斑浮腫
- 糖尿病性網膜症
- 網膜静脈閉塞症
- その他

タイプ
- ウェット型AMD
- ドライ型AMD
- 網膜萎縮

製品
- ルセンティス
- アイリーア
- アバスチン
- ビジュダイン
- その他

流通チャネル
- 病院薬局
- 小売薬局
- 眼科クリニック
- Eコマース薬局

世界市場全体とセグメントの収益予測に加え、5つの地域とxxの主要な国内市場の収益予測も掲載しています。

北米
- 米国
- カナダ

欧州
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- ロシア
- ベルギー
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- 東南アジア
- 台湾
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他のラテンアメリカの地域

MEA
- UAE
- 南アフリカ
- サウジアラビア
- クウェート
- オマーン
- カタール
- その他のMEAの地域

黄斑変性症（AMD）とその他の網膜疾患治療薬市場の2022年から2032年にかけての主要企業のプロファイルと、これらの企業のこのセグメントに焦点を当てた情報も掲載しています。

主要企業と市場成長の可能性
・ AbbVie
・ Alimera Sciences Inc.
・ Apellis Pharmaceuticals
・ Bausch ＆ Lomb
・ Bayer AG
・ Belite Bio
・ F. Hoffmann-La Roche
・ GlaxoSmithKline Pharmaceuticals Ltd.
・ GlaxoSmithKline PLC
・ Graybug Vision Inc.
・ Kubota Vision Inc.
・ Novartis AG
・ Pfizer Inc.
・ Regeneron Pharmaceuticals
・ Santen Pharmaceuticals

黄斑変性症（AMD）とその他の網膜疾患治療薬市場の世界全体の収益、2022年から2032年まで金額ベースで、市場は2022年に270億米ドルを超えると、我々の仕事は計算しています。2032年まで力強い収益成長が予測されます。本調査では、最も大きな可能性を秘めた組織を特定します。彼らの能力、進歩、商業的展望を知ることで、一歩先を行くことができます。

黄斑変性症（AMD）とその他の網膜疾患治療薬の市場、2022年から2032年までのレポートはどのように役立つのでしょうか？
270ページを超えるレポートでは、要約すると以下のような知識を得ることができます。

- 黄斑変性症（AMD）とその他の網膜疾患治療薬市場の2032年までの収益予測、プロセス、上流、下流、タイプおよび企業規模の各予測を世界および地域レベルで掲載 - 投資および収益に最も有利な場所を見つけ、業界の展望を発見することができます。

- 5地域とxx主要国市場の2032年までの収益予測 - 北米、欧州、アジア太平洋、LAMEAの黄斑変性症（AMD）とその他の網膜疾患治療薬市場、2022年から2032年の市場予測をご覧いただけます。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなど、著名な経済圏の市場も予測しています。

- 黄斑変性症（AMD）とその他の網膜疾患治療薬市場に関与する主要企業xx社の企業プロファイルを含む、既存企業および市場参入を目指す企業の展望、2022年から2032年まで。

定量的・定性的な分析と独自の予測をご覧いただけます。私たちのレポートだけが持つ情報を入手し、貴重なビジネスインテリジェンスを得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の研究、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、黄斑変性症（AMD）とその他の網膜疾患治療薬市場、2022年から2032年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測を見つけることができます。

ページTOPに戻る

1 レポートの概要
1.1 調査の目的
1.2 黄斑変性症（AMD）とその他の網膜疾患市場の紹介
1.3 本レポートが提供するもの
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する重要な質問
1.6 本レポートは誰のためのものなのか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問と回答（FAQ)
1.9 関連するVisiongainのレポート
1.10 Visiongainについて

2 エグゼクティブサマリー

3 市場の概要
3.1 主要な調査結果
3.2 マーケットダイナミクス
3.2.1 市場の推進要因
3.2.1.1 網膜疾患の発生率の増加
3.2.1.2 老年人口の増加
3.2.1.3 様々な政府による医療費支出の増加
3.2.2 市場抑制要因
3.2.2.1 ジェネリック医薬品の使用増加
3.2.2.2 AMDに関する認知度の低さ
3.2.2.3 厳しいFDA規制
3.2.3 市場機会
3.2.3.1 網膜疾患に対する最先端治療への需要の高まりが市場を後押しする
3.2.3.2 ドライ型AMD治療における未開拓のビジネスチャンス
3.2.3.3 治療のための新技術の採用の増加
3.3 COVID-19影響度分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者のバーゲニングパワー
3.4.2 バイヤーのバーゲニングパワー
3.4.3 競合他社の競争力
3.4.4 代替品による脅威
3.4.5 新規参入者の脅威
3.5 PEST分析

4 黄斑変性症（AMD）とその他の網膜疾患治療薬市場：適応症別
4.1 主要な調査結果
4.2 適応症別セグメント市場魅力度指数
4.3 黄斑変性症（AMD）とその他の網膜疾患の市場規模推定・予測：適応症別
4.4 AMD
4.4.1 地域別市場規模、2022-2032年（10億米ドル）
4.4.2 地域別市場シェア、2022年＆2032年(%)
4.5 糖尿病黄斑浮腫急成長中のセグメント
4.5.1 地域別市場規模、2022年～2032年 (10億米ドル)
4.5.2 地域別市場シェア、2022年＆2032年(%)
4.6 糖尿病網膜症市場。DMEをメインターゲットとした臨床的注目度の高い市場
4.6.1 地域別市場規模、2022年～2032年（10億米ドル）
4.6.2 地域別市場シェア、2022年＆2032年(%)
4.7 網膜静脈閉塞症市場。網膜の血管疾患の中で2番目に多い疾患
4.7.1 地域別市場規模、2022年～2032年 (10億米ドル)
4.7.2 地域別市場シェア、2022年＆2032年(%)
4.8 その他の網膜疾患市場
4.8.1 地域別市場規模、2022年〜2032年 (10億米ドル)
4.8.2 地域別市場シェア、2022年＆2032年(%)

5 黄斑変性症（AMD）とその他の網膜疾患治療薬市場：タイプ別
5.1 主な調査結果
5.2 タイプ別セグメント市場魅力度指数
5.3 黄斑変性症（AMD）とその他の網膜疾患市場規模の推定と予測：タイプ別
5.4 ウェット型AMD
5.4.1 地域別市場規模、2022-2032年（10億米ドル）
5.4.2 地域別市場シェア、2022年＆2032年(%)
5.5 ドライ型AMD
5.5.1 地域別市場規模、2022年～2032年 (10億米ドル)
5.5.2 地域別市場シェア、2022年＆2032年(%)
5.6 ジオグラフィックアトロフィー
5.6.1 地域別市場規模、2022年～2032年 (10億米ドル)
5.6.2 地域別市場シェア、2022年＆2032年(%)

6 黄斑変性症（AMD）とその他の網膜疾患治療薬市場：製品別
6.1 主要な調査結果
6.2 製品セグメント市場魅力度指数
6.3 黄斑変性症（AMD）とその他の網膜疾患市場規模の推定と予測：製品別
6.4 ルーセンティス
6.4.1 地域別市場規模、2022-2032年（10億米ドル）
6.4.2 地域別市場シェア、2022年＆2032年(%)
6.5 アイリーア
6.5.1 地域別市場規模、2022年～2032年 (10億米ドル)
6.5.2 地域別市場シェア、2022年＆2032年(%)
6.6 アバスチン
6.6.1 過去の収益が物語るwetAMDに対するアバスチンの使用増加
6.6.2 ロシュとノバルティスはCATTのヘッドライン結論に挑戦する
6.6.3 Eylea/ZaltrapはAvastinの市場ポジションに影響を与えるか？
6.6.4 Avastinの中心的地位を揺るがすものはあるか？
6.6.5 地域別市場規模、2022-2032 (億米ドル)
6.6.6 地域別市場シェア、2022年＆2032年(%)
6.7 ビズダイン
6.7.1 地域別市場規模、2022年～2032年 (10億米ドル)
6.7.2 地域別市場シェア、2022年＆2032年(%)
6.8 その他の医薬品
6.8.1 地域別市場シェア、2022年＆2032年(%)

7 黄斑変性症（AMD）とその他の網膜疾患治療薬市場：流通チャネル別
7.1 主な調査結果
7.2 流通チャネル市場魅力度指数
7.3 黄斑変性症（AMD）とその他の網膜疾患の流通チャネル別市場規模推定・予測
7.4 病院薬局
7.4.1 地域別市場規模、2022年〜2032年（10億米ドル）
7.4.2 地域別市場シェア、2022年＆2032年(%)
7.5 小売薬局
7.5.1 地域別市場規模、2022年～2032年 (10億米ドル)
7.5.2 地域別市場シェア、2022年＆2032年(%)
7.6 眼科クリニック
7.6.1 地域別市場規模、2022年～2032年 (10億米ドル)
7.6.2 地域別市場シェア、2022年＆2032年(%)
7.7 電子商取引薬局
7.7.1 地域別市場規模、2022年～2032年 (10億米ドル)
7.7.2 地域別市場シェア、2022年＆2032年(%)

8 黄斑変性症（AMD）とその他の網膜疾患市場分析：地域別
8.1 主な調査結果
8.2 地域別市場規模の推定と予測
9 ウェットAMDセグメントパイプライン分析
9.1 主要なパイプライン候補
9.2 OPT-302
9.3 GB-102
9.4 AMDとその他の網膜疾患治療のための薬剤の組み合わせ
9.4.1 抗VEGF薬とコソプト（ドルゾラミド-チモロール）薬
9.4.2 REGN 910-3とRG7716
9.4.3 抗VEGF薬とOPT-302薬
9.4.4 その他の併用療法開発

10 ドライAMDセグメントのパイプライン
10.1 Apl-2
10.2 ジムラ
10.3 副腎皮質ステロイドドライ型AMDの病態における炎症の役割を探る
10.4 神経保護。現代医学の聖杯の1つ
10.5 レネクサス（ニューロテック）。ドライ型AMDの研究において有望なデータの可能性
10.6 エラミプレチド
10.7 サブスレッショルド・ナノセカンド・レーザー
10.8 Lampalizumab

11 糖尿病網膜症領域のパイプライン
11.1 DRの開発中のステロイド
11.2 APX3330

12 北米の黄斑変性症（AMD）とその他の網膜疾患治療薬市場
12.1 主な調査結果
12.2 北米の黄斑変性症（AMD）とその他の網膜疾患国別市場 2022年、2027年＆2032年 (US$ bn)
12.3 北米の黄斑変性症（AMD）とその他の網膜疾患市場の国別市場規模予測・予想
12.4 北米の黄斑変性症（AMD）とその他の網膜疾患の適応症別市場規模予測・予測
12.5 北米の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・タイプ別予測
12.6 北米の黄斑変性症（AMD）とその他の網膜疾患市場の製品別市場規模予測・予想
12.7 北米の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・流通チャネル別予測
12.8 米国
12.9 カナダ

13 欧州の黄斑変性症（AMD）とその他の網膜疾患治療薬市場分析
13.1 主な調査結果
13.2 欧州の黄斑変性症（AMD）とその他の網膜疾患国別市場 2022年、2027年＆2032年 (US$ bn)
13.3 欧州の黄斑変性症（AMD）とその他の網膜疾患の国別市場規模予測・予想
13.4 欧州の黄斑変性症（AMD）とその他の網膜疾患の適応症別市場規模予測・予測
13.5 欧州の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・タイプ別予測
13.6 欧州の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・製品別予測
13.7 欧州の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・流通チャネル別予測
13.8 ドイツ
13.9 イギリス
13.10 フランス
13.11 イタリア
13.12 スペイン
13.13 ロシア
13.14 ベルギー
13.15 その他の欧州

14 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患市場分析
14.1 主な調査結果
14.2 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患市場の国別市場規模、2022年、2027年、2032年(US$ bn)
14.3 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患の国別市場規模予測・予想
14.4 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患の適応症別市場規模予測・予測
14.5 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・タイプ別予測
14.6 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患市場の製品別市場規模予測・予想
14.7 アジア太平洋地域の黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・流通チャネル別予測
14.8 日本
14.9 中国
14.10 インド
14.11 オーストラリア
14.12 韓国
14.13 台湾
14.14 東南アジア
14.15 その他のアジア太平洋地域

15 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患市場の分析
15.1 主要な調査結果
15.2 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患市場の国別推移、2022年、2027年、2032年(US$ bn)
15.3 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患市場の国別市場規模予測・予想
15.4 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患の適応症別市場規模予測・予測
15.5 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・タイプ別予測
15.6 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・製品別予測
15.7 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患の製品別市場規模予測・予想
15.8 ブラジル
15.9 メキシコ
15.10 アルゼンチン
15.11 ラテンアメリカのその他

16 MEAの黄斑変性症（AMD）とその他の網膜疾患の市場分析
16.1 主要な調査結果
16.2 MEAの黄斑変性症（AMD）とその他の網膜疾患市場の国別推移、2022年、2027年＆2032年(US$ bn)
16.3 MEAの黄斑変性症（AMD）とその他の網膜疾患市場の国別市場規模予測・予想
16.4 MEAの黄斑変性症（AMD）とその他の網膜疾患の適応症別市場規模の推定と予測
16.5 MEAの黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・タイプ別予測
16.6 MEAの黄斑変性症（AMD）とその他の網膜疾患市場の製品別市場規模予測・予想
16.7 MEAの黄斑変性症（AMD）とその他の網膜疾患の市場規模予測・流通チャネル別売上予測
16.8 UAE
16.9 南アフリカ
16.10 サウジアラビア
16.11 クウェート
16.12 オマーン
16.13 カタール
16.14 その他のMEA

17 主要企業のプロフィール
17.1 競合他社の状況、2021年
17.2 Novartis AG
17.2.1 会社概要
17.2.2 会社概要
17.2.3 財務分析
17.2.3.1 純収益、2017-2021年
17.2.3.2 R＆D、2017-2021年
17.2.3.3 地域別市場シェア、2021年
17.2.4 製品ベンチマーク
17.2.5 戦略的な展望
17.3 F. Hoffmann-La Roche, Ltd.
17.3.1 企業スナップショット
17.3.2 会社概要
17.3.3 財務分析
17.3.3.1 純収益、2017-2021年
17.3.3.2 R＆D、2017年～2021年
17.3.3.3 地域別市場シェア、2021年
17.3.4 製品ベンチマーク
17.3.5 戦略的な展望
17.4 GSK plc
17.4.1 企業スナップショット
17.4.2 会社概要
17.4.3 財務分析
17.4.3.1 純収益、2017-2021年
17.4.3.2 R＆D、2017-2021年
17.4.3.3 地域別市場シェア、2021年
17.4.4 製品ベンチマーク
17.5 Bayer AG
17.5.1 企業スナップショット
17.5.2 会社概要
17.5.3 財務分析
17.5.3.1 純収益、2017-2021年
17.5.3.2 R＆D、2017年-2021年
17.5.3.3 地域別市場シェア、2021年
17.5.4 製品ベンチマーク
17.5.5 戦略的な展望
17.6 Pfizer Inc.
17.6.1 企業スナップショット
17.6.2 会社概要
17.6.3 財務分析
17.6.3.1 純収益、2017-2021年
17.6.3.2 R＆D、2017年-2021年
17.6.3.3 地域別市場シェア、2021年
17.6.4 製品ベンチマーク
17.6.5 戦略的な展望
17.7 Regeneron Pharmaceuticals
17.7.1 企業スナップショット
17.7.2 会社概要
17.7.3 財務分析
17.7.3.1 純収益、2017-2021年
17.7.3.2 R＆D、2017年-2021年
17.7.3.3 地域別市場シェア、2021年
17.7.4 製品ベンチマーク
17.7.5 戦略的な展望
17.8 Bausch & Lomb Incorporated
17.8.1 企業スナップショット
17.8.2 会社概要
17.8.3 ベンチマーキング
17.8.4 戦略的展望
17.9 Apellis Pharmaceuticals
17.9.1 企業スナップショット
17.9.2 会社概要
17.9.3 ベンチマーキング
17.9.4 戦略的展望
17.10 Santen Pharmaceuticals
17.10.1 企業スナップショット
17.10.2 会社概要
17.10.3 財務分析
17.10.3.1 純収益、2017-2021年
17.10.3.2 R＆D、2017年-2021年
17.10.3.3 地域別市場シェア、2021年
17.10.4 製品ベンチマーク
17.10.5 戦略的展望
17.11 Alimera Sciences
17.11.1 企業スナップショット
17.11.2 会社概要
17.11.3 財務分析
17.11.3.1 純収益、2017-2021年
17.11.3.2 R＆D、2017年-2021年
17.11.3.3 地域別市場シェア、2021年
17.11.4 製品ベンチマーク
17.11.5 戦略的な展望
17.12 AbbVie Inc.
17.12.1 企業スナップショット
17.12.2 会社概要
17.12.3 財務分析
17.12.3.1 純収益、2017-2021年
17.12.3.2 R＆D、2017年-2021年
17.12.3.3 地域別市場シェア、2021年
17.12.4 製品ベンチマーク
17.12.5 戦略的展望
17.13 Graybug Vision Inc.
17.13.1 企業スナップショット
17.13.2 会社概要
17.13.3 ベンチマーキング
17.14 Kubota Vision Inc.
17.14.1 企業スナップショット
17.14.2 会社概要
17.14.3 ベンチマーキング
17.15 Belite Bio Inc.
17.15.1 企業スナップショット
17.15.2 会社概要
17.15.3 製品ベンチマーク

18 結論と提言
18.1 ヴィジョンゲインからの結論
18.2 市場関係者への提言

表の一覧
Table 1 Macular Degeneration (AMD) and Other Retinal Diseases Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “V” Shaped Recovery Scenario
Table 3 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “U” Shaped Recovery Scenario
Table 4 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “W” Shaped Recovery Scenario
Table 5 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “L” Shaped Recovery Scenario
Table 6 AMD and Other Disease Drugs Market Forecast by Indication: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 7 AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 8 Diabetic Macular Edema Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 9 Diabetic Retinopathy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Retinal Vein Occlusion Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 11 Other Retinal Diseases Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Global AMD and Other Disease Drugs Market Forecast by Type: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 13 Types of Choroidal Neovascularization in Wet AMD, Description: Approximate Proportion of Cases (%), 2020
Table 14 Wet AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Dry AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Geographic Atrophy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Lucentis Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 Eylea Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 Avastin Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Visudyne Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Global AMD and Other Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 24 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Ophthalmic Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 E-commerce Pharmacy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Table 29 Selected R&D Pipeline for wAMD, 2021
Table 30 Selected R&D Pipeline for Dry AMD, 2021
Table 31 Selected R&D Pipeline for DR, 2021
Table 32 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 33 Table 57 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 34 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 35 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 36 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 37 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 38 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 39 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 40 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 41 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 42 Table 57 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 43 Table 57 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 44 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 45 UK Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 46 France Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 47 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 48 Spain Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 49 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 50 Belgium Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 51 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 52 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 53 Table 57 LA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 54 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 55 Table 57 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 56 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 57 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 58 China Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 59 India Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 60 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 61 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 62 Taiwan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 63 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 65 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 67 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 68 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 69 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 70 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 72 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 73 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 74 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 75 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 76 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 77 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 78 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 79 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 80 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 81 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 82 Kuwait Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 83 Oman Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 84 Qatar Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 85 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 86 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Novartis AG: Product Benchmarking
Table 88 Novartis AG: Strategic Outlook
Table 89 F. Hoffmann-La Roche, Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 F. Hoffmann-La Roche: Product Benchmarking
Table 91 F. Hoffmann-La Roche: Strategic Outlook
Table 92 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 GSK plc: Product Benchmarking
Table 94 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Bayer AG: Product Benchmarking
Table 96 Bayer AG: Strategic Outlook
Table 97 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Pfizer Inc.: Product Benchmarking
Table 99 Pfizer Inc.: Strategic Outlook
Table 100 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Regeneron Pharmaceuticals: Product Benchmarking
Table 102 Regeneron Pharmaceuticals: Strategic Outlook
Table 103 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Bausch & Lomb: Product Benchmarking
Table 105 Bausch & Lomb: Strategic Outlook
Table 106 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Apellis Pharmaceuticals: Product Benchmarking
Table 108 Apellis Pharmaceuticals: Strategic Outlook
Table 109 Santen Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Santen Pharmaceuticals: Product Benchmarking
Table 111 Santen Pharmaceuticals: Strategic Outlook
Table 112 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Alimera Sciences: Product Benchmarking
Table 114 Alimera Sciences: Strategic Outlook
Table 115 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 AbbVie Inc.: Product Benchmarking
Table 117 AbbVie Inc.: Strategic Outlook
Table 118 Graybug Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Graybug Vision Inc.: Product Benchmarking
Table 120 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Kubota Vision Inc.: Product Benchmarking
Table 122 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Kubota Vision Inc.: Product Benchmarking

図の一覧
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Market Segmentation
Figure 2 Macular Degeneration (AMD) and Other Retinal Diseases Market by Indication: Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Market by Type: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Market by Product: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Market by Distribution Channel: Market Attractiveness Index
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Market Attractiveness Index by Region
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Market: Market Dynamics
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Market: Porter’s Five Forces Analysis
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Market: PEST Analysis
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Market by Indication: Market Attractiveness Index
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Indication, 2022, 2027, 2032 (%)
Figure 13 AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 14 AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 15 Diabetic Macular Edema Market Forecast by Region, 2022-2032 (US$ billion)
Figure 16 Diabetic Macular Edema Market Share Forecast by Region, 2022 & 2032 (%)
Figure 17 Diabetic Retinopathy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 18 Diabetic Retinopathy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Retinal Vein Occlusion Market Forecast by Region, 2022-2032 (US$ billion)
Figure 20 Retinal Vein Occlusion Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Other Retinal Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Macular Degeneration (AMD) and Other Retinal Diseases Market by Type: Market Attractiveness Index
Figure 23 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 24 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 25 Wet AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 26 Wet AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 27 Dry AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 28 Dry AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 29 Geographic Atrophy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 30 Geographic Atrophy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 31 Macular Degeneration (AMD) and Other Retinal Diseases Market by Product: Market Attractiveness Index
Figure 32 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 33 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Product, 2022, 2027, 2032 (%)
Figure 34 Lucentis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 35 Lucentis Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Drivers and Restraints for Eylea
Figure 37 Eylea Market Forecast by Region, 2022-2032 (US$ billion)
Figure 38 Eylea Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Drivers and Restraints for Avastin
Figure 40 Avastin Market Forecast by Region, 2022-2032 (US$ billion)
Figure 41 Avastin Market Share Forecast by Region, 2022 & 2032 (%)
Figure 42 Visudyne Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Visudyne Market Share Forecast by Region, 2022 & 2032 (%)
Figure 44 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 45 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Market by Distribution Channel: Market Attractiveness Index
Figure 47 Macular Degeneration (AMD) and Other Retinal Disease Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 48 Macular Degeneration (AMD) and Other Retinal Disease Market Share Forecast by Distribution Channel, 2022, 2027, 2032 (%)
Figure 49 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 50 Hospital Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 51 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 52 Retail Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 53 Ophthalmic Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 54 Ophthalmic Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 55 E-commerce Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 56 E-commerce Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 57 Macular Degeneration (AMD and Other Retinal Disease Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 58 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%))
Figure 59 North America Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 60 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 61 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 62 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 63 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Indication, 2022 & 2032 (%)
Figure 64 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 65 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 66 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 67 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 68 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 69 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 70 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 71 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 72 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 73 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 74 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 75 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 76 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Technology, 2022-2032 (US$ billion)
Figure 77 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 78 UK Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 79 France Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 80 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Spain Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 82 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 83 Belgium Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 84 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 85 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 86 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 87 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 88 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 89 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 90 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 91 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 92 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 93 China Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 94 India Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 95 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 Taiwan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 101 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 102 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 103 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 104 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 105 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Technology, 2022-2032 (US$ billion)
Figure 106 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 107 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 108 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 109 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 110 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 111 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 112 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 113 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 114 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 115 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 116 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Kuwait Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 120 Oman Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 Qatar Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 122 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 123 Macular Degeneration (AMD) and Other Retinal Diseases Market: Company Share/Ranking, 2021
Figure 124 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 125 Novartis AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 126 Novartis AG: Regional Market Shares, 2021
Figure 127 F. Hoffmann-La Roche: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 F. Hoffmann-La Roche: R&D, 2017-2021 (US$ million, AGR%)
Figure 129 F. Hoffmann-La Roche: Regional Market Shares, 2021
Figure 130 GSK plc: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 131 GSK plc: R&D, 2017-2021 (US$ million, AGR%)
Figure 132 GSK plc: Regional Market Shares, 2021
Figure 133 Bayer AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 134 Bayer AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 135 Bayer AG: Regional Market Shares, 2021
Figure 136 Pfizer Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 137 Pfizer Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 138 Pfizer Inc.: Regional Market Shares, 2021
Figure 139 Regeneron Pharmaceuticals: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 Regeneron Pharmaceuticals: R&D, 2017-2021 (US$ million, AGR%)
Figure 141 Regeneron Pharmaceuticals: Regional Market Shares, 2021
Figure 142 Santen Pharmaceuticals: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 143 Santen Pharmaceuticals: R&D, 2017-2021 (US$ million, AGR%)
Figure 144 Santen Pharmaceuticals: Regional Market Shares, 2021
Figure 145 Alimera Sciences: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Alimera Sciences: R&D, 2017-2021 (US$ million, AGR%)
Figure 147 Alimera Sciences: Regional Market Shares, 2021
Figure 148 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 149 AbbVie Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 150 AbbVie Inc.: Regional Market Shares, 2021

ページTOPに戻る

Table of Contents

Summary

Report Details

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise in Incidence of Retinal Disorders
In developing nations, the pattern of retinal blindness has evolved through time. Prior to ten years ago, hereditary retinal problems were the primary factor in visual impairment brought on by retinal diseases. Retinal blindness has several important and growing causes, including diabetic retinopathy, age-related macular degeneration (AMD), and retinopathy of prematurity (ROP). By 2025, there are projected to be 57 million diabetics and 137 million persons over the age of 65 living in India. There will be more than 42 million diabetics in developed countries and more than 82 million in developing countries by the year 2030, according to estimates. In developing nations, the prevalence of AMD ranges from 0.6% to 1.1%, with the exception of Pakistan and Bangladesh. According to WHO standards, there are 1.5 million blind children globally, with 1 million of them living in Asia, 0.3 million in Africa, 0.1 million in Latin America, and 0.1 million elsewhere. ROP can occur anywhere between 21 and 40% of the time in the newborn intensive care unit (NICU) or after a referral to a tertiary care institution. To combat this preventable and treatable retinal cause of blindness, the adoption of measures such as health education and promotion, easily accessible eye care services, infrastructure strengthening, and affordable technologies may be helpful.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market evolving?
• What is driving and restraining the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market?
• How will each Macular Degeneration (AMD) and Other Retinal Diseases Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Macular Degeneration (AMD) and Other Retinal Diseases Drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Macular Degeneration (AMD) and Other Retinal Diseases Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Macular Degeneration (AMD) and Other Retinal Diseases Drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of Macular Degeneration (AMD) and Other Retinal Diseases Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market?
• Where is the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market today, and over the next 10 years:
• Our 276-page report provides 123 tables and 150 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Macular Degeneration (AMD) and Other Retinal Diseases Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Indication
• AMD
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Others

Type
• Wet AMD
• Dry AMD
• Geographic Atrophy

Product
• Lucentis
• Eylea
• Avastin
• Visudyne
• Others

Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Ophthalmic Clinics
• E-commerce Pharmacy

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and xx leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Belgium
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South East Asia
• Taiwan
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• UAE
• South Africa
• Saudi Arabia
• Kuwait
• Oman
• Qatar
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie
• Alimera Sciences Inc.
• Apellis Pharmaceuticals
• Bausch & Lomb
• Bayer AG
• Belite Bio
• F. Hoffmann-La Roche
• GlaxoSmithKline Pharmaceuticals Ltd.
• GlaxoSmithKline PLC
• Graybug Vision Inc.
• Kubota Vision Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Santen Pharmaceuticals

Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 in terms of value the market will surpass US$27.0 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 report help you?
In summary, our 270+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 Market, with forecasts for process, upstream, downstream, type and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and xx key national markets – See forecasts for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for xx of the major companies involved in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rise in Incidence of Retinal Disorders
3.2.1.2 Upsurge in Geriatric Population
3.2.1.3 Rising Healthcare Expenditure by Various Governments
3.2.2 Market Restraining Factors
3.2.2.1 Increasing Use of Generic Drugs
3.2.2.2 Lack of Awareness Regarding AMD
3.2.2.3 Stringent FDA Regulations
3.2.3 Market Opportunities
3.2.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Disorders to Aid Market
3.2.3.2 Untapped Opportunities for the Dry-AMD Treatment
3.2.3.3 Increasing adoption of New Technologies for Treatment
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis

4 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Indication
4.1 Key Findings
4.2 Indication Segment: Market Attractiveness Index
4.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
4.4 AMD
4.4.1 Market Size by Region, 2022-2032 (US$ bn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 Diabetic Macular Edema: Fastest Growing Segment
4.5.1 Market Size by Region, 2022-2032 (US$ bn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
4.6 Diabetic Retinopathy Market: Coming into Clinical Focus, with DME the Main Target
4.6.1 Market Size by Region, 2022-2032 (US$ bn)
4.6.2 Market Share by Region, 2022 & 2032 (%)
4.7 Retinal Vein Occlusion Market: The Second Most Common Vascular Disease of The Retina
4.7.1 Market Size by Region, 2022-2032 (US$ bn)
4.7.2 Market Share by Region, 2022 & 2032 (%)
4.8 Other Retinal Diseases Market
4.8.1 Market Size by Region, 2022-2032 (US$ bn)
4.8.2 Market Share by Region, 2022 & 2032 (%)

5 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Type
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
5.4 Wet AMD
5.4.1 Market Size by Region, 2022-2032 (US$ bn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.5 Dry AMD
5.5.1 Market Size by Region, 2022-2032 (US$ bn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.6 Geographic Atrophy
5.6.1 Market Size by Region, 2022-2032 (US$ bn)
5.6.2 Market Share by Region, 2022 & 2032 (%)

6 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Product
6.1 Key Findings
6.2 Product Segment: Market Attractiveness Index
6.3 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
6.4 Lucentis
6.4.1 Market Size by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Eylea
6.5.1 Market Size by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Avastin
6.6.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
6.6.2 Roche and Novartis Challenge CATTs Headline Conclusions
6.6.3 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
6.6.4 Will Anything Dislodge Avastin from its Central Position?
6.6.5 Market Size by Region, 2022-2032 (US$ bn)
6.6.6 Market Share by Region, 2022 & 2032 (%)
6.7 Visudyne
6.7.1 Market Size by Region, 2022-2032 (US$ bn)
6.7.2 Market Share by Region, 2022 & 2032 (%)
6.8 Other Drugs
6.8.1 Market Share by Region, 2022 & 2032 (%)

7 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel: Market Attractiveness Index
7.3 Macular Degeneration (AMD) and Other Retinal Disease Market Size Estimation and Forecast by Distribution Channel
7.4 Hospital Pharmacy
7.4.1 Market Size by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 Retail Pharmacy
7.5.1 Market Size by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Ophthalmic Clinics
7.6.1 Market Size by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)
7.7 E-commerce Pharmacy
7.7.1 Market Size by Region, 2022-2032 (US$ bn)
7.7.2 Market Share by Region, 2022 & 2032 (%)

8 Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 Wet AMD Segment: Pipeline Analysis
9.1 The Leading Pipeline Candidates
9.2 OPT-302
9.3 GB-102
9.4 Combination of Drugs for the Treatment of AMD and Other Retinal Diseases
9.4.1 Anti-VEGF and Cosopt (Dorzolamide-timolol) Drugs
9.4.2 REGN 910-3 and RG7716
9.4.3 Anti-VEGF and OPT-302 Drugs
9.4.4 Others Combination Therapy Developments

10 Pipeline for Dry AMD Segment
10.1 Apl-2
10.2 Zimura
10.3 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
10.4 Neuroprotection: One of Modern Medicine's Holy Grails
10.5 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
10.6 Elamipretide
10.7 Subthreshold Nanosecond Laser
10.8 Lampalizumab

11 Pipeline for Diabetic Retinopathy Segment
11.1 Steroids in Development for DR
11.2 APX3330

12 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market
12.1 Key Findings
12.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
12.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
12.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
12.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
12.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
12.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
12.8 U.S.
12.9 Canada

13 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Analysis
13.1 Key Findings
13.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
13.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
13.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
13.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
13.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
13.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
13.8 Germany
13.9 UK
13.10 France
13.11 Italy
13.12 Spain
13.13 Russia
13.14 Belgium
13.15 Rest of Europe

14 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis
14.1 Key Findings
14.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
14.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
14.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
14.5 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
14.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
14.7 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
14.8 Japan
14.9 China
14.10 India
14.11 Australia
14.12 South Korea
14.13 Taiwan
14.14 South East Asia
14.15 Rest of Asia Pacific

15 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis
15.1 Key Findings
15.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
15.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
15.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
15.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
15.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
15.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
15.8 Brazil
15.9 Mexico
15.10 Argentina
15.11 Rest of Latin America

16 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis
16.1 Key Findings
16.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market by Country, 2022, 2027 & 2032 (US$ bn)
16.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Country
16.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Indication
16.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Type
16.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Product
16.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Size Estimation and Forecast by Distribution Channel
16.8 UAE
16.9 South Africa
16.10 Saudi Arabia
16.11 Kuwait
16.12 Oman
16.13 Qatar
16.14 Rest of MEA

17 Company Profiles
17.1 Competitive Landscape, 2021
17.2 Novartis AG
17.2.1 Company Snapshot
17.2.2 Company Overview
17.2.3 Financial Analysis
17.2.3.1 Net Revenue, 2017-2021
17.2.3.2 R&D, 2017-2021
17.2.3.3 Regional Market Shares, 2021
17.2.4 Product Benchmarking
17.2.5 Strategic Outlook
17.3 F. Hoffmann-La Roche, Ltd.
17.3.1 Company Snapshot
17.3.2 Company Overview
17.3.3 Financial Analysis
17.3.3.1 Net Revenue, 2017-2021
17.3.3.2 R&D, 2017-2021
17.3.3.3 Regional Market Shares, 2021
17.3.4 Product Benchmarking
17.3.5 Strategic Outlook
17.4 GSK plc
17.4.1 Company Snapshot
17.4.2 Company Overview
17.4.3 Financial Analysis
17.4.3.1 Net Revenue, 2017-2021
17.4.3.2 R&D, 2017-2021
17.4.3.3 Regional Market Shares, 2021
17.4.4 Product Benchmarking
17.5 Bayer AG
17.5.1 Company Snapshot
17.5.2 Company Overview
17.5.3 Financial Analysis
17.5.3.1 Net Revenue, 2017-2021
17.5.3.2 R&D, 2017-2021
17.5.3.3 Regional Market Shares, 2021
17.5.4 Product Benchmarking
17.5.5 Strategic Outlook
17.6 Pfizer Inc.
17.6.1 Company Snapshot
17.6.2 Company Overview
17.6.3 Financial Analysis
17.6.3.1 Net Revenue, 2017-2021
17.6.3.2 R&D, 2017-2021
17.6.3.3 Regional Market Shares, 2021
17.6.4 Product Benchmarking
17.6.5 Strategic Outlook
17.7 Regeneron Pharmaceuticals
17.7.1 Company Snapshot
17.7.2 Company Overview
17.7.3 Financial Analysis
17.7.3.1 Net Revenue, 2017-2021
17.7.3.2 R&D, 2017-2021
17.7.3.3 Regional Market Shares, 2021
17.7.4 Product Benchmarking
17.7.5 Strategic Outlook
17.8 Bausch & Lomb Incorporated
17.8.1 Company Snapshot
17.8.2 Company Overview
17.8.3 Product Benchmarking
17.8.4 Strategic Outlook
17.9 Apellis Pharmaceuticals
17.9.1 Company Snapshot
17.9.2 Company Overview
17.9.3 Product Benchmarking
17.9.4 Strategic Outlook
17.10 Santen Pharmaceuticals
17.10.1 Company Snapshot
17.10.2 Company Overview
17.10.3 Financial Analysis
17.10.3.1 Net Revenue, 2017-2021
17.10.3.2 R&D, 2017-2021
17.10.3.3 Regional Market Shares, 2021
17.10.4 Product Benchmarking
17.10.5 Strategic Outlook
17.11 Alimera Sciences
17.11.1 Company Snapshot
17.11.2 Company Overview
17.11.3 Financial Analysis
17.11.3.1 Net Revenue, 2017-2021
17.11.3.2 R&D, 2017-2021
17.11.3.3 Regional Market Shares, 2021
17.11.4 Product Benchmarking
17.11.5 Strategic Outlook
17.12 AbbVie Inc.
17.12.1 Company Snapshot
17.12.2 Company Overview
17.12.3 Financial Analysis
17.12.3.1 Net Revenue, 2017-2021
17.12.3.2 R&D, 2017-2021
17.12.3.3 Regional Market Shares, 2021
17.12.4 Product Benchmarking
17.12.5 Strategic Outlook
17.13 Graybug Vision Inc.
17.13.1 Company Snapshot
17.13.2 Company Overview
17.13.3 Product Benchmarking
17.14 Kubota Vision Inc.
17.14.1 Company Snapshot
17.14.2 Company Overview
17.14.3 Product Benchmarking
17.15Belite Bio Inc.
17.15.1 Company Snapshot
17.15.2 Company Overview
17.15.3 Product Benchmarking

18 Conclusion and Recommendations
18.1 Concluding Remarks from Visiongain
18.2 Recommendations for Market Players

List of Tables
Table 1 Macular Degeneration (AMD) and Other Retinal Diseases Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “V” Shaped Recovery Scenario
Table 3 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “U” Shaped Recovery Scenario
Table 4 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “W” Shaped Recovery Scenario
Table 5 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%)): “L” Shaped Recovery Scenario
Table 6 AMD and Other Disease Drugs Market Forecast by Indication: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 7 AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 8 Diabetic Macular Edema Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 9 Diabetic Retinopathy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 10 Retinal Vein Occlusion Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 11 Other Retinal Diseases Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 12 Global AMD and Other Disease Drugs Market Forecast by Type: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 13 Types of Choroidal Neovascularization in Wet AMD, Description: Approximate Proportion of Cases (%), 2020
Table 14 Wet AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 15 Dry AMD Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 16 Geographic Atrophy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 17 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 18 Lucentis Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 19 Eylea Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 20 Avastin Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 21 Visudyne Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 22 Others Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 23 Global AMD and Other Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2022-2032
Table 24 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 25 Retail Pharmacies Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 26 Ophthalmic Clinics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 27 E-commerce Pharmacy Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%), CAGR (%))
Table 29 Selected R&D Pipeline for wAMD, 2021
Table 30 Selected R&D Pipeline for Dry AMD, 2021
Table 31 Selected R&D Pipeline for DR, 2021
Table 32 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 33 Table 57 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 34 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 35 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 36 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 37 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 38 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 39 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 40 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 41 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 42 Table 57 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 43 Table 57 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 44 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 45 UK Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 46 France Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 47 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 48 Spain Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 49 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 50 Belgium Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 51 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 52 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 53 Table 57 LA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 54 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 55 Table 57 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 56 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 57 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 58 China Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 59 India Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 60 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 61 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 62 Taiwan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 63 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 64 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 65 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 67 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 68 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 69 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 70 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 72 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 73 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 74 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 75 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 76 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 77 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 78 Table 57 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 79 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 80 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 81 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 82 Kuwait Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 83 Oman Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 84 Qatar Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 85 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 86 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Novartis AG: Product Benchmarking
Table 88 Novartis AG: Strategic Outlook
Table 89 F. Hoffmann-La Roche, Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 F. Hoffmann-La Roche: Product Benchmarking
Table 91 F. Hoffmann-La Roche: Strategic Outlook
Table 92 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 GSK plc: Product Benchmarking
Table 94 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 95 Bayer AG: Product Benchmarking
Table 96 Bayer AG: Strategic Outlook
Table 97 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 98 Pfizer Inc.: Product Benchmarking
Table 99 Pfizer Inc.: Strategic Outlook
Table 100 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 101 Regeneron Pharmaceuticals: Product Benchmarking
Table 102 Regeneron Pharmaceuticals: Strategic Outlook
Table 103 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Bausch & Lomb: Product Benchmarking
Table 105 Bausch & Lomb: Strategic Outlook
Table 106 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Apellis Pharmaceuticals: Product Benchmarking
Table 108 Apellis Pharmaceuticals: Strategic Outlook
Table 109 Santen Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 Santen Pharmaceuticals: Product Benchmarking
Table 111 Santen Pharmaceuticals: Strategic Outlook
Table 112 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Alimera Sciences: Product Benchmarking
Table 114 Alimera Sciences: Strategic Outlook
Table 115 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 AbbVie Inc.: Product Benchmarking
Table 117 AbbVie Inc.: Strategic Outlook
Table 118 Graybug Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Graybug Vision Inc.: Product Benchmarking
Table 120 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Kubota Vision Inc.: Product Benchmarking
Table 122 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 123 Kubota Vision Inc.: Product Benchmarking

List of Figures
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Market Segmentation
Figure 2 Macular Degeneration (AMD) and Other Retinal Diseases Market by Indication: Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Market by Type: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Market by Product: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Market by Distribution Channel: Market Attractiveness Index
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Market Attractiveness Index by Region
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Market: Market Dynamics
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Market: Porter’s Five Forces Analysis
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Market: PEST Analysis
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Market by Indication: Market Attractiveness Index
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Indication, 2022, 2027, 2032 (%)
Figure 13 AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 14 AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 15 Diabetic Macular Edema Market Forecast by Region, 2022-2032 (US$ billion)
Figure 16 Diabetic Macular Edema Market Share Forecast by Region, 2022 & 2032 (%)
Figure 17 Diabetic Retinopathy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 18 Diabetic Retinopathy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 19 Retinal Vein Occlusion Market Forecast by Region, 2022-2032 (US$ billion)
Figure 20 Retinal Vein Occlusion Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 Other Retinal Diseases Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Macular Degeneration (AMD) and Other Retinal Diseases Market by Type: Market Attractiveness Index
Figure 23 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 24 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 25 Wet AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 26 Wet AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 27 Dry AMD Market Forecast by Region, 2022-2032 (US$ billion)
Figure 28 Dry AMD Market Share Forecast by Region, 2022 & 2032 (%)
Figure 29 Geographic Atrophy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 30 Geographic Atrophy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 31 Macular Degeneration (AMD) and Other Retinal Diseases Market by Product: Market Attractiveness Index
Figure 32 Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 33 Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Product, 2022, 2027, 2032 (%)
Figure 34 Lucentis Market Forecast by Region, 2022-2032 (US$ billion)
Figure 35 Lucentis Market Share Forecast by Region, 2022 & 2032 (%)
Figure 36 Drivers and Restraints for Eylea
Figure 37 Eylea Market Forecast by Region, 2022-2032 (US$ billion)
Figure 38 Eylea Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Drivers and Restraints for Avastin
Figure 40 Avastin Market Forecast by Region, 2022-2032 (US$ billion)
Figure 41 Avastin Market Share Forecast by Region, 2022 & 2032 (%)
Figure 42 Visudyne Market Forecast by Region, 2022-2032 (US$ billion)
Figure 43 Visudyne Market Share Forecast by Region, 2022 & 2032 (%)
Figure 44 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 45 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Market by Distribution Channel: Market Attractiveness Index
Figure 47 Macular Degeneration (AMD) and Other Retinal Disease Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 48 Macular Degeneration (AMD) and Other Retinal Disease Market Share Forecast by Distribution Channel, 2022, 2027, 2032 (%)
Figure 49 Hospital Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 50 Hospital Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 51 Retail Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 52 Retail Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 53 Ophthalmic Clinics Market Forecast by Region, 2022-2032 (US$ billion)
Figure 54 Ophthalmic Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 55 E-commerce Pharmacy Market Forecast by Region, 2022-2032 (US$ billion)
Figure 56 E-commerce Pharmacy Market Share Forecast by Region, 2022 & 2032 (%)
Figure 57 Macular Degeneration (AMD and Other Retinal Disease Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 58 Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022-2032 (US$ bn, AGR (%))
Figure 59 North America Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 60 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 61 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 62 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 63 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Indication, 2022 & 2032 (%)
Figure 64 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 65 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 66 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 67 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
Figure 68 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 69 Canada Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 70 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 71 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 72 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 73 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 74 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 75 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 76 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Technology, 2022-2032 (US$ billion)
Figure 77 Germany Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 78 UK Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 79 France Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 80 Italy Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 81 Spain Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 82 Russia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 83 Belgium Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 84 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 85 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 86 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 87 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Share Forecast by Country, 2022 & 2032 (%)
Figure 88 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 89 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 90 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 91 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 92 Japan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 93 China Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 94 India Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 95 Australia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 96 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 97 Taiwan Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 98 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 99 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 101 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 102 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 103 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 104 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 105 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Technology, 2022-2032 (US$ billion)
Figure 106 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 107 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 108 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 109 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 110 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 111 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Country, 2022-2032 (US$ billion)
Figure 112 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Indication, 2022-2032 (US$ billion)
Figure 113 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Type, 2022-2032 (US$ billion)
Figure 114 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Product, 2022-2032 (US$ billion)
Figure 115 MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast by Distribution Channel, 2022-2032 (US$ billion)
Figure 116 UAE Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 119 Kuwait Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 120 Oman Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 121 Qatar Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 122 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 123 Macular Degeneration (AMD) and Other Retinal Diseases Market: Company Share/Ranking, 2021
Figure 124 Novartis AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 125 Novartis AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 126 Novartis AG: Regional Market Shares, 2021
Figure 127 F. Hoffmann-La Roche: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 F. Hoffmann-La Roche: R&D, 2017-2021 (US$ million, AGR%)
Figure 129 F. Hoffmann-La Roche: Regional Market Shares, 2021
Figure 130 GSK plc: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 131 GSK plc: R&D, 2017-2021 (US$ million, AGR%)
Figure 132 GSK plc: Regional Market Shares, 2021
Figure 133 Bayer AG: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 134 Bayer AG: R&D, 2017-2021 (US$ million, AGR%)
Figure 135 Bayer AG: Regional Market Shares, 2021
Figure 136 Pfizer Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 137 Pfizer Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 138 Pfizer Inc.: Regional Market Shares, 2021
Figure 139 Regeneron Pharmaceuticals: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 140 Regeneron Pharmaceuticals: R&D, 2017-2021 (US$ million, AGR%)
Figure 141 Regeneron Pharmaceuticals: Regional Market Shares, 2021
Figure 142 Santen Pharmaceuticals: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 143 Santen Pharmaceuticals: R&D, 2017-2021 (US$ million, AGR%)
Figure 144 Santen Pharmaceuticals: Regional Market Shares, 2021
Figure 145 Alimera Sciences: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 146 Alimera Sciences: R&D, 2017-2021 (US$ million, AGR%)
Figure 147 Alimera Sciences: Regional Market Shares, 2021
Figure 148 AbbVie Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 149 AbbVie Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 150 AbbVie Inc.: Regional Market Shares, 2021

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（AMD）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

黄斑変性症（AMD）とその他の網膜疾患治療薬の市場レポート：2022-2032

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（AMD）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?